Skip to main content
. 2015 Jan 5;74(3):480–489. doi: 10.1136/annrheumdis-2014-206624

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Meta-analyses of all cardiovascular events and individual cardiovascular events in patients with rheumatoid arthritis treated with (A) tumour necrosis factor inhibitors; (B) methotrexate; (C) non-steroidal anti-inflammatory drugs; or (D) corticosteroids in controlled studies. Size of data markers indicates relative weight of the study (from random-effects analysis). COX-2, cyclooxygenase-2; CVE, cardiovascular event; MACE, major adverse cardiac event; MTX, methotrexate; RR, relative risk; TNFi, tumour necrosis factor inhibitor.